Metabolism

WAYLIVRA (volanesorsen): An Antisense Oligonucleotide Inhibitor of Apolipoprotein CIII (apoCIII) mRNA - Market Size, Forecasts, and Emerging Insights, 2019-2023 and 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, General Health, Pharmaceutical, Health, Head, Metabolism, Apolipoprotein, Ionis Pharmaceuticals, Genetic disorder, Messenger, Connective tissue, SWOT, EU4, Weight, Volanesorsen, Triglyceride, Therapy, FPL, Chylomicron, CIII, Clinical trial, Adipose tissue, Research, Pharmaceutical industry

Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.

Key Points: 
  • Further, it also consists of future market assessments inclusive of the WAYLIVRA market forecast analysis for lipodystrophy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in lipodystrophy.
  • WAYLIVRA (volanesorsen), an antisense oligonucleotide inhibitor of apolipoprotein CIII (apoCIII) mRNA, is being developed by Ionis Pharmaceuticals through its subsidiary company, Akcea Therapeutics to treat familial partial lipodystrophy (FPL).
  • Volanesorsen is an antisense oligonucleotide that binds to apoC-III mRNA, leading to its degradation and preventing the translation of apoC-III protein.
  • What are the other emerging products available and how are these giving competition to WAYLIVRA for lipodystrophy?

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024
FDA, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Tardive dyskinesia, Chorea, VMAT2, Metabolism, EVP, Deuterium, Annual report, TEVA, Marketing, Teva, Partnership, HD, Quality of life, Food, Schizophrenia, Neurological disorder, DSM-IV codes, Globalization, Neuro, Prevalence, Happy Mood, Face, Anesthesia, Central nervous system disease, Pivot, Tongue, CNS, Psychiatry, Patient, Pain, Disease, Extremities, Research, Pharmaceutical industry

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Retrieved on: 
Friday, February 23, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Metabolism, AstraZeneca, Hypereosinophilic syndrome, Chronic pain, Growth, Skin, Fatigue, Immunology, Polyp (medicine), Efficacy, COPD, Biopharmaceutical, Social media, Placebo, Safety, Treatment, Chronic obstructive pulmonary disease, ClinicalTrials.gov, Abstract (summary), Respiratory Medicine, OCS, Bell, Rash, Biomarker, Heart, HES, Sinusitis, Inflammation, Weight loss, Asthma, Gastrointestinal tract, Death, OLE, Disease, Pharmaceutical industry

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.

Key Points: 
  • AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases.
  • Fasenra met the primary endpoint in the MANDARA Phase III trial in eosinophilic granulomatosis with polyangiitis (EGPA).
  • Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
  • A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES) (NATRON).

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Retrieved on: 
Friday, February 23, 2024
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Therapy, AstraZeneca, Metabolism, SVP, Silence Therapeutics, Polycythemia, RNA, DSM-IV codes, Clinical trial, Small RNA, Biopharmaceutical, Pharmaceutical industry

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

Key Points: 
  • Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.
  • “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the clinic from our mRNAi GOLD™ platform,” said Craig Tooman, President and CEO of Silence.
  • Silence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence’s proprietary mRNAi GOLD™ platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases.
  • Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination.

Immunis Chairman Dr. Hans Keirstead is an Invited Speaker at the 2024 Brain Trust Conference

Retrieved on: 
Friday, February 23, 2024
Biotechnology, Pharmaceutical, Health, Therapy, Brain trust, Heart, Metabolism, Intelligence, Immunomodulation, Conference

Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.

Key Points: 
  • Immunis, Inc. , a private biotech company revolutionizing cellular secretome therapeutics, is proud to announce that its Chairman, Dr. Hans Keirstead , will present at the exclusive 13D Brain Trust Conference in the Bahamas.
  • Brain Trust is a highly exclusive, invite-only event covering artificial intelligence, global technological advancements, innovative biotechnology, and unique investment opportunities.
  • Like its name, the Brain Trust Conference invites the world’s greatest minds to realize their visions for the world.
  • We thank the Brain Trust Conference for honoring Dr. Keirstead as a guest speaker and for including Immunis in the atmosphere of intellectual exchange to propel humanity forward.

No-Cost Heart & Kidney Health Screening Available on February 20th, 21st, and 22nd at Texas Southern University

Retrieved on: 
Wednesday, February 21, 2024
Women, Seniors, Practice Management, FDA, Research, Diabetes, Men, Family, Other Health, Consumer, Pharmaceutical, Hospitals, Genetics, Fitness & Nutrition, Clinical Trials, Cardiology, Biotechnology, University, Health, Education, Science, Texas Southern University, Metabolism, Clinical trial, Future, Access, Exercise, Stroke, Risk, Prevalence, Health education, Medicine, Heart, Kidney, Pharmaceutical industry

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Texas Southern University in Houston, Texas.

Key Points: 
  • Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Texas Southern University in Houston, Texas.
  • The Heart & Kidney Health Screening offers no-cost Lp(a) testing as well as screenings for other related metabolism and kidney risks.
  • Health Education: Information to raise awareness about cardiovascular health and the importance of clinical research in advancing medical treatments.
  • Care Access will host screening events on February 20-22 at Texas Southern University, 3100 Cleburne Street, Houston, Texas 77030.

Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer

Retrieved on: 
Monday, February 19, 2024
Biotechnology, FDA, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Science, Clinical Trials, Metabolism, Immunotherapy, AstraZeneca, News, Daiichi Sankyo, National Cancer Institute, Lung cancer, Triple-negative breast cancer, Immunology, Patient, Cleavage, Biopharmaceutical, Social media, Progression-free survival, Treatment, BLA, Docetaxel, IHC, DXD, Pharmacotherapy, NSCLC, Breast cancer, Gefitinib, PD-1, Safety, Lung, Pemetrexed, PFS, American Cancer Society, Pircher, Observational study, MD, Sapporo Medical University, Food, Cancer, ADC, OS, Immunoglobulin G, Death, Medicine, Pharmaceutical industry

AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.

Key Points: 
  • AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy.
  • In patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful PFS benefit and a numerically favorable OS trend.
  • Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Datopotamab deruxtecan has the potential to offer patients with previously treated advanced nonsquamous non-small cell lung cancer an effective and tolerable alternative to conventional chemotherapy.
  • Additional regulatory submissions for datopotamab deruxtecan in lung and breast cancer are underway globally.

BioIVT to Showcase Leading Products for Toxicological Studies at the SOT ToxExpo 2024

Retrieved on: 
Thursday, March 7, 2024
Metabolism, SOT, Doctor of Philosophy, Research, Prodrug, Drug development, DDI, Society of Toxicology, Hall, Immune system, Learning, Cell, Poster, CES, Biotransformation, ADME, Medical device

WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .

Key Points: 
  • WESTBURY, N.Y., March 7, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced its presence and scientific contributions at the 2024 Society of Toxicology (SOT) 63rd Annual Meeting and ToxExpo .
  • "The BioIVT team attending SOT includes experts from across our product portfolios.
  • We look forward to meeting with research colleagues and learning how we can support their programs," he added.
  • Visit BioIVT on the show floor at booth #1509 or schedule a time to connect with us and learn more: https://bioivt.com/about/events?entry=SOT+ToxExpo+2024

FROM HACKATHON TO HEALING: BIG DATA SOLUTIONS TO BREAST CANCER CHALLENGES

Retrieved on: 
Wednesday, March 6, 2024
Data science, Breast cancer, Metabolism, Indiana University, Mission, Doctor of Philosophy, University of Notre Dame, Neoplasm, Database, Life, Cell, Risk, University, Human, Breast, Creativity, Patient, Oncology, Disease, Machine learning, Advocate, DRS, Research, Student

Susan G. Komen ®, the world's leading breast cancer organization, plays a pivotal role as a convenor of researchers and patient advocates who can work together, share ideas and utilize big data approaches to address immediate needs or identify outstanding challenges in the fight against breast cancer.

Key Points: 
  • Susan G. Komen ®, the world's leading breast cancer organization, plays a pivotal role as a convenor of researchers and patient advocates who can work together, share ideas and utilize big data approaches to address immediate needs or identify outstanding challenges in the fight against breast cancer.
  • Susan G. Komen, along with partners UT Southwestern and Lyda Hill Philanthropies, held its first Breast Cancer Hackathon Challenge in 2023 where 54 participants – representing 5 countries, 20 U.S. States and 34 institutions – had 48 hours to address one of three breast cancer challenges using publicly-available patient and/or pre-clinical data.
  • The participants included students, oncologists, breast cancer researchers and data scientists, all bringing their own skillset to the fight against breast cancer.
  • The three compelling challenges addressed during the Hackathon were:
    Topic 1: Predict and visualize combined functional effects of germline (present at birth) and somatic (acquired in life) mutations in breast cancer.

Life Time Shares Five Common Food Imposters to Promote Healthy Choices this National Nutrition Month

Retrieved on: 
Wednesday, March 6, 2024
Olive, Honey, Experience, Cheese, Metabolism, Nutrition, Real, Farmer, Micronutrient, Starch, Deception, Scallion, Food, Cellulose, Coffee, Olive oil, Palm oil, LTH, Eating

CHANHASSEN, Minn., March 6, 2024  /PRNewswire/ -- The landscape of food is complex – and it's only getting worse. Ensuring you're buying genuine, healthy ingredients is increasingly challenging because of misleading labels on products that mask bad items in otherwise healthy-looking choices at the grocery store.

Key Points: 
  • Ensuring you're buying genuine, healthy ingredients is increasingly challenging because of misleading labels on products that mask bad items in otherwise healthy-looking choices at the grocery store.
  • To help everyone recognize the good from the bad, Life Time (NYSE: LTH), offers five "healthy" food favorites that can sneakily hide harmful fillers and cheap, unhealthy substitutes.
  • By avoiding pre-ground coffee, you can eliminate the potential for these imposters and enjoy a fresher-tasting brew.
  • Maple Syrup: Cherished for its natural sweetness, maple syrup – like honey – is one of the most common categories full of imposters.